David Wholley assumed the position as Executive Vice-President, Strategy and Business Development in May 2022. He served as the Interim President and Executive Director from September 2021 until May 2022, as the organization transitioned to new leadership. Before that, he managed the Research Partnerships Division of the Foundation, which is responsible for major research collaborations including the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), Accelerating Medicines Partnership® Program (AMP®), the Biomarkers Consortium, the LungMAP precision medicine trial in lung cancer, and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Prior to joining the Foundation in 2006, Mr. Wholley’s career spanned nearly 25 years in healthcare technology business management, including extensive experience in product development, sales, marketing, corporate strategy, and partnership and project development. Mr. Wholley has held senior management roles in several venture-funded technology startup companies, including head of Global Marketing and Development for First Genetic Trust, Inc., which developed software for large-scale collaborative genetic research and personalized medicine. During a 16-year career at IBM, he co-led the corporate strategy team that guided IBM’s formation of its Life Sciences industry organization. Mr. Wholley holds an M.Phil. from Rutgers University and a Certificate in Business Administration from the Stern School of Business at New York University.
Current role